Highlighted Article Flyer for the journal “Current Cancer Drug Targets”

CCDT-Articles_17-9- Suaib Luqman

http://www.eurekaselect.com/584/journal/current-cancer-drug-targets

 

Testimonial by Saeed Samarghandian!

Saeed Samarghandian

Contributed Article: Anti-Carcinogenic Effects of Carnosol-An Updated Review

Highlighted Article Flyer for the journal “CNS & Neurological Disorders – Drug Targets”

Geoffrey Burnstock

http://www.eurekaselect.com/145703/article

New Issue :: Current Drug Targets 18, Issue 5

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

cdt

Articles from the journal Current Drug Targets 18, Issue 5:

For details on the articles, please visit this link :: http://bit.ly/2qG6EQM

 

Wishing A Very Happy Birthday Dr. Joseph Varon!

Dr. Joseph Varon

Dr. Joseph Varon

Editor-in-Chief: Current Respiratory Medicine Reviews

The University of Texas Health Science Center
Houston, TX
USA

New Issue :: Current Nanoscience 13, Issue 2

Current Nanoscience publishes authoritative reviews, original research and highlights, written by experts in the field on all the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano-structures, nano-bubbles, nano-droplets, nanofluids, synthesis, properties, assembly and devices. Applications of nanoscience in biotechnology, medicine, pharmaceuticals, physics, material science and electronics are also covered. The journal is essential to all involved in nanoscience and its applied areas.

cnano

Articles from the journal Current Nanoscience 13, Issue 2:

For details on the articles, please visit this link :: http://bit.ly/2rkNLDM

 

 

 

Testimonial by Hamada Abd El-Aziz!

Hamada Abd El-Aziz

Contributed Article: CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping, and Synthesis

Article by Disease – “Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study”

Article by Disease on “Cardiology

Abstract:

Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment.

Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee- 8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those 60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives.

Results: Hypertensive patients (n=760; mean age: 51±10 years; 67% were males) were included. A total of 178 patients (23%) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87% (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99% and 98%, respectively; p<0.001).

Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.

Read more: http://www.eurekaselect.com/node/144156/article

New Issue :: Applied Clinical Research, Clinical Trials and Regulatory Affairs 4, Issue 1

Applied Clinical Research, Clinical Trials and Regulatory Affairs is an international journal with market leadership in readership and contributions that are scientific, original, relevant, innovative and statistically validated. The journal aims to further bridge the gap in the publication of clinical drug development and regulatory affairs between high growth and potentially growing regions.

The journal Applied Clinical Research, Clinical Trials and Regulatory Affairs publishes innovative, developmental and original research on validated experimental design, methods, representation and interpretation of clinical research and drug trials. Additionally, the journal publishes original research articles, reviews, short communications and thematic journal issues. Published work is based on solid clinical, scientific and statistically relevant results that lead to advancements in clinical medicine, clinical research, regulatory affairs and human subject protection in the areas of biological advances, drugs, bio-therapeutics and devices.

ACRCTRA

Articles from the journal Applied Clinical Research, Clinical Trials and Regulatory Affairs 4, Issue 1:

For details on the articles, please visit this link :: http://bit.ly/2rxUDLv

 

Highlighted Article Flyer for the journal “Current Medicinal Chemistry”

CMC-Articles_24-42- Pasquale Pagliaro

http://www.eurekaselect.com/602/journal/current-medicinal-chemistry